 Mutated Genes and Abnormal Protein Expression
|
| Gene | Location | Topics
|
| HSPCA (
HSP90A
, HSPC1
)
|
|
-HSPCA and Breast Cancer
|
| BCAR2 |
|
-BCAR2 and Breast Cancer
|
| BCAR3 (
NSP2
)
|
|
-BCAR3 and Breast Cancer
|
| GSTM1 (
GST1
, MU
)
| 1p13.3
|
-GSTM1 and Breast Cancer
|
| ARHC (
RhoC
)
| 1p21-p13
|
-RhoC Overexpression in Inflammatory Breast Cancer
|
| MUC1 (
PUM
, PEM
)
| 1q21
|
-MUC1 and Breast Cancer
|
| S100A4 (
MTS1
, P9KA
, metastasin
)
| 1q21
|
-S100A4 and Breast Cancer
|
| KISS1 (
KiSS-1
)
| 1q32
|
-KISS1 and Breast Cancer
|
| CYP1B1 (
GLC3A
)
| 2p22-p21
|
-CYP1B1 Polymorphisms in Breast Cancer
|
| SRD5A2 | 2p23
|
-SRD5A2 and Breast Cancer
|
| BIN1 (
AMPHL
, SH3P9
)
| 2q14
|
-BIN1 and Breast Cancer
|
| BARD1 | 2q34-q35
|
|
| ARHA (
ARH12
, RhoA
)
| 3p21.3
|
-RhoA Overexpression in Breast Cancer
|
| TGFBR2 | 3p22
|
-TGFBR2 in EHLA and Risk of Breast Cancer
|
| RARB (
NR1B2
, HAP
)
| 3p24
|
-RARB Expression in Breast Cancer
|
| EIF4E (
EIF-4E
)
| 4q21-q25
|
-EIF4E in Breast Cancer
|
| HSPCB (
HSP90B
, HSPC2
)
| 6p12
|
-HSPCB and Breast Cancer
|
| TFAP2B (
AP2B
)
| 6p12
|
-TFAP2B Expression in Breast cancer
|
| NOTCH4 (
INT3
, NOTCH3
)
| 6p21.3
|
-NOTCH4 and Breast Cancer
|
| TFAP2A (
AP2
, AP2TF
)
| 6p24
|
-TFAP2A Expression in Breast Cancer
|
| LIBC | 6q22
|
|
| TPD52L1 (
D53
, hD53
)
| 6q22-q23
|
|
| ESR1 (
ESRA
)
| 6q25.1
|
-ESR1 and Breast Cancer
|
| AMPH | 7p14-p13
|
-AMPH Expression in Breast Cancer
|
| IL6 (
IFNB2
)
| 7p21
|
-IL-6 Expression in Breast Cancer
|
| HSPB1 (
HSP27
)
| 7q
|
-HSP27 and Breast Cancer
|
| TPD52 (
D52
)
| 8q21
|
|
| EIF3S6 (
INT6
)
| 8q22-q23
|
|
| MYC (
CMYC
, C-MYC
)
| 8q24.12-q24.13
|
-MYC and Breast Cancer
|
| BAG1 | 9p12
|
-BAG1 and Breast Cancer
|
| CDKN2A (
P16
, INK4A
, MTS1
)
| 9p21
|
-CDKN2A Mutation and Breast Cancer
|
| COT (
MAP3K8
, TPL-2
, EST
)
| 10p11.2
|
-COT Over Expression and Amplification in Breast Cancer
|
| SNCG (
BCSG1
)
| 10q23.2-q23.3
|
|
| FGF8 (
AIGF
)
| 10q24
|
-FGF8 Over-Expression in Breast Cancer
|
| PLAU (
uPA
, URK
)
| 10q24
|
-uPA Expression and Breast Cancer Prognosis
|
| CYP17 | 10q24.3
|
-CYP17 and Breast Cancer
|
| MKI67 (
Ki-67
)
| 10q25-qter
|
-Ki-67 and Breast Cancer Proliferation (MIB-1 assay)
|
| STIP1 (
HSP70
)
| 11?
|
-HSP70 and Breast Cancer
|
| TSG101 | 11p15.2-p15.1
|
|
| HRAS | 11p15.5
|
-HRAS Minisatellite Alleles and Breast Cancer Risk
|
| IGF2 | 11p15.5
|
-IGF2 and Breast Cancer
|
| CTSD (
CPSD
)
| 11p15.5
|
-Cathepsin D Expression in Breast Cancer
-Cathepsin D Expression in Breast Cancer
-Cathepsin D and Prognosis in Breast Cancer
|
| SLC22A1L (
BWSCR1A
, ORCTL2
, IMPT1
)
| 11p15.5
|
-SLC22A1L and Breast Cancer ?
|
| CD44 (
MDU3
, HA
, MDU2
)
| 11pter-p13
|
-CD44 and Breast Cancer
|
| EMS1 | 11q13
|
-EMS1 and Breast Cancer
|
| CCND1 (
D11S287E
, Cyclin D
, PRAD1
)
| 11q13
|
-CCND1 and Breast Cancer
|
| GSTP1 (
FAEES3
, GST3
, PI
)
| 11q13
|
-GSTP1 Polymorphisms and Breast Cancer
|
| ATM (
ATA
, ATC
)
| 11q22.3
|
-Ataxia-telangiectasia and Risk of Breast Cancer
|
| CDKN1B (
KIP1
, P27
)
| 12p13
|
-CDKN1B and Breast Cancer
|
| CD9 (
p24
, MIC3
, BA2
)
| 12p13
|
-CD9 and Breast Cancer
|
| ERBB3 (
HER3
)
| 12q13
|
|
| IGF1 | 12q22-q24.1
|
-IGF1 Expression in Breast Cancer
|
| BRCA2 | 13q12.3
|
-BRCA2 and Breast Cancer
-BRCA2 in Familial Breast Cancer
-BRCA2 and Outcome in Breast Cancer
-BRCA2 and Breast Cancer During Pregnancy
|
| RB1 (
Rb
)
| 13q14.2
|
-RB1 and Breast Cancer
|
| EFNB2 (
EPLG5
, LERK5
, ephrin-B2
)
| 13q33
|
-EFNB2 Expression and Breast Cancer
|
| ING1 | 13q34
|
-ING1 Supression in Breast Cancer
|
| ESR2 (
ESRB
, ERBeta
)
| 14q
|
-ESR2 and Breast Cancer
|
| CYP19 | 15q21.1
|
-CYP19 Polymorphisms and Breast Cancer Risk
|
| CYP1A1 (
CYP1
)
| 15q22-q24
|
-CYP1A1 and Breast Cancer
|
| CSK (
c-src
)
| 15q23-q25
|
-CSK and Breast Cancer
|
| IGF1R (
JTK13
)
| 15q25-q26
|
-IGF1R and Breast Cancer
|
| MMP2 (
CLG4A
, CLG4
, GELA
)
| 16q13
|
-MMP2 and Breast Cancer
|
| BCAR1 | 16q23.1
|
-BCAR1 Expression and Breast Cancer
-BCAR1 and Tamoxifen Resistance in Breast Cancer
-BCAR1 Expression and Prognosis in Breast Cancer
|
| MAP2K4 (
MKK4
, SEK1
, JNKK1
)
| 17p11.2
|
-MAP2K4 Mutations in Breast Cancer
|
| TP53 (
p53
, P53
)
| 17p13.1
|
-TP53 and Breast Cancer
|
| LASP1 (
MLN50
)
| 17q11-q21.3
|
-LASP1 Expression in Breast Cancer
|
| ERBB2 (
HER2
, NEU
)
| 17q11.2-q12
|
-ERBB2 and Breast Cancer
-anti-HER2 Monoclonal Antibody in Breast Cancer Treatment
-ERBB2 and Benign Breast Lesions
-ERBB2 and Mammary Paget's disease
|
| BRCA1 | 17q21
|
-BRCA1 Screening
-BRCA1 and Breast Cancer
|
| TIMP2 | 17q25
|
-TIMP2 and Breast Cancer
|
| BIRC5 (
survivin
, SVV
, API4
)
| 17q25(?)
|
-Survivin Expression in Breast Cancer
|
| PI5 (
maspin
)
| 18q21.3
|
-Maspin and Breast Cancer
|
| STK11 (
LKB1
, PJS
)
| 19p13.3
|
|
| KLK3 (
PSA
, APS
)
| 19q13
|
-Prostate Specific Antigen and Breast Cancer
|
| PCNA | 20p12
|
-PCNA and Breast Cancer
|
| TFAP2C | 20q13.2
|
-TFAP2C Expression in Breast Cancer
|
| BCAS1 (
NABC1
, AIBC1
)
| 20q13.2-q13.3
|
|
| TFF1 (
D21S21
, BCEI
)
| 21q22.3
|
|
| PSEN2 (
D21S21
, HPS2
, BCEI
)
| 21q22.3
|
-PSEN2 Expression in Breast Cancer
|
| COMT | 22q11.2
|
-COMT Polymorphisms and Breast Cancer
|
| MMP11 (
STMY3
, STR3
)
| 22q11.2
|
-MMP11 Expression in Breast Cancer
|
| GSTT1 | 22q11.23 ?
|
-GSTT1 Polymorphisms and Breast Cancer
|
| CHEK2 (
CHK2
, RAD53
, CDS1
)
| 22q12.1
|
-CHEK2 mutations in Breast Cancer
|
|
Breast Cancer: Clinical and Epidemiological Resources